Zolimomab aritox

Zolimomab aritox is a monoclonal antibody designed for the treatment of cancer. It was developed by Peregrine Pharmaceuticals, a biopharmaceutical company specializing in the development and manufacturing of therapeutics to treat cancer and other life-threatening diseases.

Mechanism of Action

Zolimomab aritox works by binding to the CD22 antigen on the surface of B cells, which are a type of white blood cell. The CD22 antigen is often overexpressed in certain types of cancer, including non-Hodgkin lymphoma and chronic lymphocytic leukemia. Once bound, zolimomab aritox delivers a toxic payload to the cancer cells, causing them to die.

Clinical Trials

Zolimomab aritox has undergone several clinical trials to assess its safety and efficacy in treating cancer. In a Phase I trial, the drug was found to be well-tolerated and showed promising results in patients with refractory non-Hodgkin lymphoma. However, further development of the drug was halted due to financial constraints.

Potential Side Effects

Like all drugs, zolimomab aritox can cause side effects. The most common side effects reported in clinical trials include fatigue, nausea, and fever. Serious side effects can include anaphylaxis, a severe allergic reaction.

Future Research

While the development of zolimomab aritox has been halted, research into CD22-targeted therapies continues. These therapies hold promise for the treatment of B-cell malignancies and other diseases where the CD22 antigen is overexpressed.

This article is a stub related to pharmacology. You can help WikiMD by expanding it!